查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
单纯疱疹病毒治疗市场：按类型、按药物类型、按分销渠道：全球机会分析和行业预测，2021-2031 年
市场调查报告书
商品编码
1266411

单纯疱疹病毒治疗市场：按类型、按药物类型、按分销渠道：全球机会分析和行业预测，2021-2031 年

Herpes Simplex Virus Treatment Market By Type, By Drug type, By Distribution channel : Global Opportunity Analysis and Industry Forecast, 2021-2031
出版日期: | 出版商: Allied Market Research | 英文 349 Pages | 商品交期: 2-3个工作天内

价格

2021 年单纯疱疹病毒治疗市场规模为 172427 万美元，预计 2031 年将达到 212691 万美元，从 2022 年到 2031 年的复合年增长率为 2.1%。

单纯疱疹病毒 (HSV) 是一种常见的病毒感染，影响着全世界许多人。 单纯疱疹病毒有两种类型，1□□ 型 (HSV-1) 和 2 型 (HSV-2)。 HSV-1 通常与唇疱疹有关，唇疱疹会导致口腔周围出现唇疱疹和热水泡。 这种类型的疱疹在通过口交感染时也会引起生殖器疱疹。 HSV-2 是生殖器疱疹最常见的病因，但通过生殖器与口腔接触感染时也会引起唇疱疹。 HSV 可以通过性接触传播，病毒也可以通过其他方式传播。 单纯疱疹病毒的治疗包括抗病毒药物、外用乳膏或软膏以及控制症状的家庭疗法。 抗病毒药物的使用在治疗这种疾病方面显示出可喜的结果。

单纯疱疹病毒治疗的全球市场受到疱疹病毒感染上升的显着推动。 此外，与单纯疱疹病毒相关的研发活动增加以及片剂和乳膏等新配方的开发预计将推动市场增长。 例如，德国生物製药公司AiCuris Anti-infective Cures AG正在研发一种治疗HSV感染的新型抗病毒药物（Pritelivir）。 这种药物“Pritelivir”是通过抑制病毒复製来发挥作用的，在临床试验中已经证实可以有效减少病毒脱落和感染频率。 因此，单纯疱疹病毒的研发活动十分活跃，推动了市场的增长。

另一方面，在欠发达国家，对性传播感染 (STI) 和疱疹病毒等疾病的认识不足阻碍了市场增长。 然而，随着对疱疹感染认识的提高，越来越多的人正在接受检测和诊断。 这增加了发达国家对有效治疗的需求。

此外，预计在预测期内，亚太地区和 LAMEA 地区新兴经济体的单纯疱疹病毒药物的开发和批准以及增长机会将推动市场增长。 例如，2020 年 11 月，Amneal Pharmaceuticals, LLC 宣布了缩写 Acyclovir Cream，5%，是 Zovirax 的仿製药，用于治疗免疫功能低下的成人和 12 岁及以上青少年的复发性唇疱疹（冷敏感性）。宣布它已获得美国食品和药物管理局 (FDA) 的申请 (ANDA) 批准*。

单纯疱疹病毒治疗市场分为类型、药物类型、分销渠道和地区。 按类型分为单纯疱疹病毒1型感染和单纯疱疹病毒2型感染。 按药物类型分为阿昔洛韦、伐昔洛韦和泛昔洛韦。 按销售渠道划分，它分为医院药房、药店和零售药房以及在线供应商。 按地区划分，北美（美国、加拿大、墨西哥）、欧洲（德国、法国、英国、意大利、西班牙、欧洲其他地区）、亚太地区（日本、中国、澳大利亚、印度、韩国、亚太地区其他地区），亚洲 它在太平洋地区（巴西、阿拉伯、澳大利亚、韩国、亚洲其他地区）进行了分析。

内容

第一章介绍

第 2 章执行摘要

第 3 章市场概述

  • 市场定义和范围
  • 主要发现
    • 顶级影响因子
    • 顶级投资基金
  • 波特的五力分析
    • 供应商的议价能力
    • 买家的议价能力
    • 替代品的威胁
    • 新进入者的威胁
    • 竞争对手的实力
  • 市场动态
    • 司机
      • 单纯疱疹病毒 (HSV) 感染率上升
      • 提高对单纯疱疹病毒的认识
    • 约束因素
      • 围绕单纯疱疹病毒的耻辱
    • 机会
      • 增加研发活动
      • 新兴经济体的高增长潜力
  • 分析 COVID-19 对市场的影响

第 4 章单纯疱疹病毒治疗市场：按类型

  • 概览
    • 市场规模和预测
  • 单纯疱疹病毒 1 型感染
    • 主要市场趋势、增长动力和机遇
    • 市场规模和预测：按地区
    • 市场份额分析：国家/地区分析
  • 单纯疱疹病毒 2 型感染
    • 主要市场趋势、增长动力和机遇
    • 市场规模和预测：按地区
    • 市场份额分析：国家/地区分析

第 5 章单纯疱疹病毒治疗市场：按药物类型分类

  • 概览
    • 市场规模和预测
  • 阿昔洛韦
    • 主要市场趋势、增长动力和机遇
    • 市场规模和预测：按地区
    • 市场份额分析：国家/地区分析
  • 伐昔洛韦
    • 主要市场趋势、增长动力和机遇
    • 市场规模和预测：按地区
    • 市场份额分析：国家/地区分析
  • 泛昔洛韦
    • 主要市场趋势、增长动力和机遇
    • 市场规模和预测：按地区
    • 市场份额分析：国家/地区分析

第 6 章单纯疱疹病毒治疗市场：按分销渠道

  • 概览
    • 市场规模和预测
  • 医院药房
    • 主要市场趋势、增长动力和机遇
    • 市场规模和预测：按地区
    • 市场份额分析：国家/地区分析
  • 药店和零售药店
    • 主要市场趋势、增长动力和机遇
    • 市场规模和预测：按地区
    • 市场份额分析：国家/地区分析
  • 在线提供商
    • 主要市场趋势、增长动力和机遇
    • 市场规模和预测：按地区
    • 市场份额分析：国家/地区分析

第 7 章单纯疱疹病毒治疗市场：按地区

  • 概览
    • 市场规模和预测：按地区
  • 北美
    • 主要趋势和机会
    • 市场规模/预测：按类型
    • 市场规模和预测：按药物类型
    • 市场规模和预测：按分销渠道
    • 市场规模/预测：按国家/地区分类
      • 美国
      • 主要市场趋势、增长动力和机遇
      • 市场规模/预测：按类型
      • 市场规模和预测：按药物类型
      • 市场规模和预测：按分销渠道
      • 加拿大
      • 主要市场趋势、增长动力和机遇
      • 市场规模/预测：按类型
      • 市场规模和预测：按药物类型
      • 市场规模和预测：按分销渠道
      • 墨西哥
      • 主要市场趋势、增长动力和机遇
      • 市场规模/预测：按类型
      • 市场规模和预测：按药物类型
      • 市场规模和预测：按分销渠道
  • 欧洲
    • 主要趋势和机会
    • 市场规模/预测：按类型
    • 市场规模和预测：按药物类型
    • 市场规模和预测：按分销渠道
    • 市场规模/预测：按国家/地区分类
      • 德国
      • 主要市场趋势、增长动力和机遇
      • 市场规模/预测：按类型
      • 市场规模和预测：按药物类型
      • 市场规模和预测：按分销渠道
      • 法国
      • 主要市场趋势、增长动力和机遇
      • 市场规模/预测：按类型
      • 市场规模和预测：按药物类型
      • 市场规模和预测：按分销渠道
      • 英国
      • 主要市场趋势、增长动力和机遇
      • 市场规模/预测：按类型
      • 市场规模和预测：按药物类型
      • 市场规模和预测：按分销渠道
      • 意大利
      • 主要市场趋势、增长动力和机遇
      • 市场规模/预测：按类型
      • 市场规模和预测：按药物类型
      • 市场规模和预测：按分销渠道
      • 西班牙
      • 主要市场趋势、增长动力和机遇
      • 市场规模/预测：按类型
      • 市场规模和预测：按药物类型
      • 市场规模和预测：按分销渠道
      • 其他欧洲
      • 主要市场趋势、增长动力和机遇
      • 市场规模/预测：按类型
      • 市场规模和预测：按药物类型
      • 市场规模和预测：按分销渠道
  • 亚太地区
    • 主要趋势和机会
    • 市场规模/预测：按类型
    • 市场规模和预测：按药物类型
    • 市场规模和预测：按分销渠道
    • 市场规模/预测：按国家/地区分类
      • 日本
      • 主要市场趋势、增长动力和机遇
      • 市场规模/预测：按类型
      • 市场规模和预测：按药物类型
      • 市场规模和预测：按分销渠道
      • 中国
      • 主要市场趋势、增长动力和机遇
      • 市场规模/预测：按类型
      • 市场规模和预测：按药物类型
      • 市场规模和预测：按分销渠道
      • 印度
      • 主要市场趋势、增长动力和机遇
      • 市场规模/预测：按类型
      • 市场规模和预测：按药物类型
      • 市场规模和预测：按分销渠道
      • 澳大利亚
      • 主要市场趋势、增长动力和机遇
      • 市场规模/预测：按类型
      • 市场规模和预测：按药物类型
      • 市场规模和预测：按分销渠道
      • 韩国
      • 主要市场趋势、增长动力和机遇
      • 市场规模/预测：按类型
      • 市场规模和预测：按药物类型
      • 市场规模和预测：按分销渠道
      • 其他亚太地区
      • 主要市场趋势、增长动力和机遇
      • 市场规模/预测：按类型
      • 市场规模和预测：按药物类型
      • 市场规模和预测：按分销渠道
  • 拉美
    • 主要趋势和机会
    • 市场规模/预测：按类型
    • 市场规模和预测：按药物类型
    • 市场规模和预测：按分销渠道
    • 市场规模/预测：按国家/地区分类
      • 巴西
      • 主要市场趋势、增长动力和机遇
      • 市场规模/预测：按类型
      • 市场规模和预测：按药物类型
      • 市场规模和预测：按分销渠道
      • 沙特阿拉伯
      • 主要市场趋势、增长动力和机遇
      • 市场规模/预测：按类型
      • 市场规模和预测：按药物类型
      • 市场规模/预测：分布
      • 南非
      • 主要市场趋势、增长动力和机遇
      • 市场规模/预测：按类型
      • 市场规模和预测：按药物类型
      • 市场规模和预测：按分销渠道
      • LAMEA 的其余部分
      • 主要市场趋势、增长动力和机遇
      • 市场规模/预测：按类型
      • 市场规模和预测：按药物类型
      • 市场规模和预测：按分销渠道

第八章竞争格局

  • 介绍
  • 关键成功策略
  • 10 家主要公司的产品映射
  • 比赛仪表板
  • 竞争热图
  • 定位顶级公司，2021 年

第九章公司简介

  • Abbott Laboratories
  • GlaxoSmithKline plc
  • Glenmark Pharmaceuticals Limited
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Novartis AG
  • Fresenius SE and Co. KGaA
  • Amneal Pharmaceuticals LLC
  • Emcure Pharmaceuticals Limited
Product Code: A13199

The herpes simplex virus treatment market size valued for $1,724.27 million in 2021 and is estimated to reach $2,126.91 million by 2031, exhibiting a CAGR of 2.1% from 2022 to 2031.  

Herpes simplex virus (HSV) is a common viral infection that affects many people worldwide. There are two types of herpes simplex virus including type 1 (HSV-1) and type 2 (HSV-2). HSV-1 is usually associated with oral herpes, causing cold sores or fever blisters around the mouth. This type of herpes also causes genital herpes if it is transmitted through oral sex. HSV-2 is the most common cause of genital herpes, but it also causes oral herpes if it is transmitted through genital-to-oral contact. HSV can spread through sexual contact and virus also be transmitted in other ways. Herpes simplex virus treatment includes antiviral medications, topical creams or ointments, and home remedies to manage symptoms. The use of antiviral drugs has shown promising results in treating the disease.* 

The global herpes simplex virus treatment market is majorly driven by increase in the incidences of herpes viral infections. In addition, rise in R&D activities for herpes simplex virus and development of newer & advanced formulations, such as tablets and creams, are expected to fuel the market growth. For instance, AiCuris Anti-infective Cures AG is a German biopharmaceutical company that is developing a new antiviral drug (Pritelivir) for the treatment of HSV infections. This drug, Pritelivir, works by inhibiting the virus from replicating and has been shown to be effective in reducing viral shedding and the frequency of infections in clinical trials. Thus, rise in R&D activities for herpes simplex virus propels the market growth.* 

In contrast, limited awareness about the diseases such as sexually transmitted infections (STIs) and herpes virus in underdeveloped countries impedes the growth of the market. However, there is an increase in awareness of herpes infections, with rise in number of people are getting tested and diagnosed. This leads to increase in the demand for effective treatments in developed countries.*** 

Moreover, development and approvals of drugs for herpes simplex virus and growth opportunities in the emerging economies of Asia-Pacific and LAMEA regions are anticipated to drive the market growth during the forecast period. For instance, in November 2020, Amneal Pharmaceuticals, LLC announced that it has received the approval for its Abbreviated New Drug Application (ANDA) from the U.S. Food and Drug Administration (FDA) for Acyclovir Cream, 5%, a generic version of Zovirax for treatment of recurrent herpes labialis (cold sores) in immunocompetent adults and adolescents 12 years of age and older.* 

The herpes simplex virus treatment market is segmented into type, drug type, distribution channel, and region. By type, the market is categorized into herpes simplex virus-1 infection, and herpes simplex virus-2 infection. By drug type, the market is classified into acyclovir, valacyclovir, and famciclovir. By distribution channel, the market is divided into hospital pharmacies, drug stores & retail pharmacies, and online providers. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).* 

Major key players that operate in the global herpes simplex virus treatment market are: Abbott Laboratories, Amneal Pharmaceuticals LLC., Emcure Pharmaceuticals Limited, Fresenius SE & Co. KGaA, GlaxoSmithKline plc, Glenmark Pharmaceuticals Limited, Pfizer Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., and Viatris Inc.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the herpes simplex virus treatment market analysis from 2021 to 2031 to identify the prevailing herpes simplex virus treatment market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the herpes simplex virus treatment market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global herpes simplex virus treatment market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By  Type

  • Herpes simplex virus-1 infection
  • Herpes simplex virus-2 infection

By  Drug type

  • Acyclovir
  • Valacyclovir
  • Famciclovir

By Distribution channel

  • Hospital pharmacies
  • Drug store and retail pharmacies
  • Online providers

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players

  • Viatris Inc.
  • Abbott Laboratories
  • GlaxoSmithKline plc
  • Pfizer Inc.
  • Fresenius SE and Co. KGaA
  • Amneal Pharmaceuticals LLC
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd.
  • Glenmark Pharmaceuticals Limited
  • Emcure Pharmaceuticals Limited

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research Methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. Bargaining power of suppliers
    • 3.3.2. Bargaining power of buyers
    • 3.3.3. Threat of substitutes
    • 3.3.4. Threat of new entrants
    • 3.3.5. Intensity of rivalry
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Rise in prevalence of herpes simplex virus (HSV) infection
      • 3.4.1.2. Increase in awareness about herpes simplex virus
    • 3.4.2. Restraints
      • 3.4.2.1. Stigma associated with herpes simplex virus
    • 3.4.3. Opportunities
      • 3.4.3.1. Increase in R&D activities
      • 3.4.3.2. High growth potential in developing economies
  • 3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  TYPE

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Herpes simplex virus-1 infection
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. Herpes simplex virus-2 infection
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country

CHAPTER 5: HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  DRUG TYPE

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Acyclovir
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Valacyclovir
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country
  • 5.4. Famciclovir
    • 5.4.1. Key market trends, growth factors and opportunities
    • 5.4.2. Market size and forecast, by region
    • 5.4.3. Market share analysis by country

CHAPTER 6: HERPES SIMPLEX VIRUS TREATMENT MARKET, BY DISTRIBUTION CHANNEL

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. Hospital pharmacies
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by region
    • 6.2.3. Market share analysis by country
  • 6.3. Drug store and retail pharmacies
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by region
    • 6.3.3. Market share analysis by country
  • 6.4. Online providers
    • 6.4.1. Key market trends, growth factors and opportunities
    • 6.4.2. Market size and forecast, by region
    • 6.4.3. Market share analysis by country

CHAPTER 7: HERPES SIMPLEX VIRUS TREATMENT MARKET, BY REGION

  • 7.1. Overview
    • 7.1.1. Market size and forecast By Region
  • 7.2. North America
    • 7.2.1. Key trends and opportunities
    • 7.2.2. Market size and forecast, by  Type
    • 7.2.3. Market size and forecast, by  Drug type
    • 7.2.4. Market size and forecast, by Distribution channel
    • 7.2.5. Market size and forecast, by country
      • 7.2.5.1. U.S.
      • 7.2.5.1.1. Key market trends, growth factors and opportunities
      • 7.2.5.1.2. Market size and forecast, by  Type
      • 7.2.5.1.3. Market size and forecast, by  Drug type
      • 7.2.5.1.4. Market size and forecast, by Distribution channel
      • 7.2.5.2. Canada
      • 7.2.5.2.1. Key market trends, growth factors and opportunities
      • 7.2.5.2.2. Market size and forecast, by  Type
      • 7.2.5.2.3. Market size and forecast, by  Drug type
      • 7.2.5.2.4. Market size and forecast, by Distribution channel
      • 7.2.5.3. Mexico
      • 7.2.5.3.1. Key market trends, growth factors and opportunities
      • 7.2.5.3.2. Market size and forecast, by  Type
      • 7.2.5.3.3. Market size and forecast, by  Drug type
      • 7.2.5.3.4. Market size and forecast, by Distribution channel
  • 7.3. Europe
    • 7.3.1. Key trends and opportunities
    • 7.3.2. Market size and forecast, by  Type
    • 7.3.3. Market size and forecast, by  Drug type
    • 7.3.4. Market size and forecast, by Distribution channel
    • 7.3.5. Market size and forecast, by country
      • 7.3.5.1. Germany
      • 7.3.5.1.1. Key market trends, growth factors and opportunities
      • 7.3.5.1.2. Market size and forecast, by  Type
      • 7.3.5.1.3. Market size and forecast, by  Drug type
      • 7.3.5.1.4. Market size and forecast, by Distribution channel
      • 7.3.5.2. France
      • 7.3.5.2.1. Key market trends, growth factors and opportunities
      • 7.3.5.2.2. Market size and forecast, by  Type
      • 7.3.5.2.3. Market size and forecast, by  Drug type
      • 7.3.5.2.4. Market size and forecast, by Distribution channel
      • 7.3.5.3. UK
      • 7.3.5.3.1. Key market trends, growth factors and opportunities
      • 7.3.5.3.2. Market size and forecast, by  Type
      • 7.3.5.3.3. Market size and forecast, by  Drug type
      • 7.3.5.3.4. Market size and forecast, by Distribution channel
      • 7.3.5.4. Italy
      • 7.3.5.4.1. Key market trends, growth factors and opportunities
      • 7.3.5.4.2. Market size and forecast, by  Type
      • 7.3.5.4.3. Market size and forecast, by  Drug type
      • 7.3.5.4.4. Market size and forecast, by Distribution channel
      • 7.3.5.5. Spain
      • 7.3.5.5.1. Key market trends, growth factors and opportunities
      • 7.3.5.5.2. Market size and forecast, by  Type
      • 7.3.5.5.3. Market size and forecast, by  Drug type
      • 7.3.5.5.4. Market size and forecast, by Distribution channel
      • 7.3.5.6. Rest of Europe
      • 7.3.5.6.1. Key market trends, growth factors and opportunities
      • 7.3.5.6.2. Market size and forecast, by  Type
      • 7.3.5.6.3. Market size and forecast, by  Drug type
      • 7.3.5.6.4. Market size and forecast, by Distribution channel
  • 7.4. Asia-Pacific
    • 7.4.1. Key trends and opportunities
    • 7.4.2. Market size and forecast, by  Type
    • 7.4.3. Market size and forecast, by  Drug type
    • 7.4.4. Market size and forecast, by Distribution channel
    • 7.4.5. Market size and forecast, by country
      • 7.4.5.1. Japan
      • 7.4.5.1.1. Key market trends, growth factors and opportunities
      • 7.4.5.1.2. Market size and forecast, by  Type
      • 7.4.5.1.3. Market size and forecast, by  Drug type
      • 7.4.5.1.4. Market size and forecast, by Distribution channel
      • 7.4.5.2. China
      • 7.4.5.2.1. Key market trends, growth factors and opportunities
      • 7.4.5.2.2. Market size and forecast, by  Type
      • 7.4.5.2.3. Market size and forecast, by  Drug type
      • 7.4.5.2.4. Market size and forecast, by Distribution channel
      • 7.4.5.3. India
      • 7.4.5.3.1. Key market trends, growth factors and opportunities
      • 7.4.5.3.2. Market size and forecast, by  Type
      • 7.4.5.3.3. Market size and forecast, by  Drug type
      • 7.4.5.3.4. Market size and forecast, by Distribution channel
      • 7.4.5.4. Australia
      • 7.4.5.4.1. Key market trends, growth factors and opportunities
      • 7.4.5.4.2. Market size and forecast, by  Type
      • 7.4.5.4.3. Market size and forecast, by  Drug type
      • 7.4.5.4.4. Market size and forecast, by Distribution channel
      • 7.4.5.5. South Korea
      • 7.4.5.5.1. Key market trends, growth factors and opportunities
      • 7.4.5.5.2. Market size and forecast, by  Type
      • 7.4.5.5.3. Market size and forecast, by  Drug type
      • 7.4.5.5.4. Market size and forecast, by Distribution channel
      • 7.4.5.6. Rest of Asia-Pacific
      • 7.4.5.6.1. Key market trends, growth factors and opportunities
      • 7.4.5.6.2. Market size and forecast, by  Type
      • 7.4.5.6.3. Market size and forecast, by  Drug type
      • 7.4.5.6.4. Market size and forecast, by Distribution channel
  • 7.5. LAMEA
    • 7.5.1. Key trends and opportunities
    • 7.5.2. Market size and forecast, by  Type
    • 7.5.3. Market size and forecast, by  Drug type
    • 7.5.4. Market size and forecast, by Distribution channel
    • 7.5.5. Market size and forecast, by country
      • 7.5.5.1. Brazil
      • 7.5.5.1.1. Key market trends, growth factors and opportunities
      • 7.5.5.1.2. Market size and forecast, by  Type
      • 7.5.5.1.3. Market size and forecast, by  Drug type
      • 7.5.5.1.4. Market size and forecast, by Distribution channel
      • 7.5.5.2. Saudi Arabia
      • 7.5.5.2.1. Key market trends, growth factors and opportunities
      • 7.5.5.2.2. Market size and forecast, by  Type
      • 7.5.5.2.3. Market size and forecast, by  Drug type
      • 7.5.5.2.4. Market size and forecast, by Distribution channel
      • 7.5.5.3. South Africa
      • 7.5.5.3.1. Key market trends, growth factors and opportunities
      • 7.5.5.3.2. Market size and forecast, by  Type
      • 7.5.5.3.3. Market size and forecast, by  Drug type
      • 7.5.5.3.4. Market size and forecast, by Distribution channel
      • 7.5.5.4. Rest of LAMEA
      • 7.5.5.4.1. Key market trends, growth factors and opportunities
      • 7.5.5.4.2. Market size and forecast, by  Type
      • 7.5.5.4.3. Market size and forecast, by  Drug type
      • 7.5.5.4.4. Market size and forecast, by Distribution channel

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Top player positioning, 2021

CHAPTER 9: COMPANY PROFILES

  • 9.1. Abbott Laboratories
    • 9.1.1. Company overview
    • 9.1.2. Key Executives
    • 9.1.3. Company snapshot
    • 9.1.4. Operating business segments
    • 9.1.5. Product portfolio
    • 9.1.6. Business performance
  • 9.2. GlaxoSmithKline plc
    • 9.2.1. Company overview
    • 9.2.2. Key Executives
    • 9.2.3. Company snapshot
    • 9.2.4. Operating business segments
    • 9.2.5. Product portfolio
    • 9.2.6. Business performance
  • 9.3. Glenmark Pharmaceuticals Limited
    • 9.3.1. Company overview
    • 9.3.2. Key Executives
    • 9.3.3. Company snapshot
    • 9.3.4. Operating business segments
    • 9.3.5. Product portfolio
    • 9.3.6. Business performance
  • 9.4. Pfizer Inc.
    • 9.4.1. Company overview
    • 9.4.2. Key Executives
    • 9.4.3. Company snapshot
    • 9.4.4. Operating business segments
    • 9.4.5. Product portfolio
    • 9.4.6. Business performance
  • 9.5. Teva Pharmaceutical Industries Ltd.
    • 9.5.1. Company overview
    • 9.5.2. Key Executives
    • 9.5.3. Company snapshot
    • 9.5.4. Operating business segments
    • 9.5.5. Product portfolio
    • 9.5.6. Business performance
  • 9.6. Viatris Inc.
    • 9.6.1. Company overview
    • 9.6.2. Key Executives
    • 9.6.3. Company snapshot
    • 9.6.4. Operating business segments
    • 9.6.5. Product portfolio
    • 9.6.6. Business performance
  • 9.7. Novartis AG
    • 9.7.1. Company overview
    • 9.7.2. Key Executives
    • 9.7.3. Company snapshot
    • 9.7.4. Operating business segments
    • 9.7.5. Product portfolio
    • 9.7.6. Business performance
  • 9.8. Fresenius SE and Co. KGaA
    • 9.8.1. Company overview
    • 9.8.2. Key Executives
    • 9.8.3. Company snapshot
    • 9.8.4. Operating business segments
    • 9.8.5. Product portfolio
    • 9.8.6. Business performance
  • 9.9. Amneal Pharmaceuticals LLC
    • 9.9.1. Company overview
    • 9.9.2. Key Executives
    • 9.9.3. Company snapshot
    • 9.9.4. Operating business segments
    • 9.9.5. Product portfolio
    • 9.9.6. Business performance
    • 9.9.7. Key strategic moves and developments
  • 9.10. Emcure Pharmaceuticals Limited
    • 9.10.1. Company overview
    • 9.10.2. Key Executives
    • 9.10.3. Company snapshot
    • 9.10.4. Operating business segments
    • 9.10.5. Product portfolio
    • 9.10.6. Business performance

LIST OF TABLES

  • TABLE 01. GLOBAL HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  TYPE, 2021-2031 ($MILLION)
  • TABLE 02. HERPES SIMPLEX VIRUS TREATMENT MARKET FOR HERPES SIMPLEX VIRUS-1 INFECTION, BY REGION, 2021-2031 ($MILLION)
  • TABLE 03. HERPES SIMPLEX VIRUS TREATMENT MARKET FOR HERPES SIMPLEX VIRUS-2 INFECTION, BY REGION, 2021-2031 ($MILLION)
  • TABLE 04. GLOBAL HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 05. HERPES SIMPLEX VIRUS TREATMENT MARKET FOR ACYCLOVIR, BY REGION, 2021-2031 ($MILLION)
  • TABLE 06. HERPES SIMPLEX VIRUS TREATMENT MARKET FOR VALACYCLOVIR, BY REGION, 2021-2031 ($MILLION)
  • TABLE 07. HERPES SIMPLEX VIRUS TREATMENT MARKET FOR FAMCICLOVIR, BY REGION, 2021-2031 ($MILLION)
  • TABLE 08. GLOBAL HERPES SIMPLEX VIRUS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 09. HERPES SIMPLEX VIRUS TREATMENT MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
  • TABLE 10. HERPES SIMPLEX VIRUS TREATMENT MARKET FOR DRUG STORE AND RETAIL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
  • TABLE 11. HERPES SIMPLEX VIRUS TREATMENT MARKET FOR ONLINE PROVIDERS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 12. HERPES SIMPLEX VIRUS TREATMENT MARKET, BY REGION, 2021-2031 ($MILLION)
  • TABLE 13. NORTH AMERICA HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  TYPE, 2021-2031 ($MILLION)
  • TABLE 14. NORTH AMERICA HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 15. NORTH AMERICA HERPES SIMPLEX VIRUS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 16. NORTH AMERICA HERPES SIMPLEX VIRUS TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 17. U.S. HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  TYPE, 2021-2031 ($MILLION)
  • TABLE 18. U.S. HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 19. U.S. HERPES SIMPLEX VIRUS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 20. CANADA HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  TYPE, 2021-2031 ($MILLION)
  • TABLE 21. CANADA HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 22. CANADA HERPES SIMPLEX VIRUS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 23. MEXICO HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  TYPE, 2021-2031 ($MILLION)
  • TABLE 24. MEXICO HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 25. MEXICO HERPES SIMPLEX VIRUS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 26. EUROPE HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  TYPE, 2021-2031 ($MILLION)
  • TABLE 27. EUROPE HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 28. EUROPE HERPES SIMPLEX VIRUS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 29. EUROPE HERPES SIMPLEX VIRUS TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 30. GERMANY HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  TYPE, 2021-2031 ($MILLION)
  • TABLE 31. GERMANY HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 32. GERMANY HERPES SIMPLEX VIRUS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 33. FRANCE HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  TYPE, 2021-2031 ($MILLION)
  • TABLE 34. FRANCE HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 35. FRANCE HERPES SIMPLEX VIRUS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 36. UK HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  TYPE, 2021-2031 ($MILLION)
  • TABLE 37. UK HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 38. UK HERPES SIMPLEX VIRUS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 39. ITALY HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  TYPE, 2021-2031 ($MILLION)
  • TABLE 40. ITALY HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 41. ITALY HERPES SIMPLEX VIRUS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 42. SPAIN HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  TYPE, 2021-2031 ($MILLION)
  • TABLE 43. SPAIN HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 44. SPAIN HERPES SIMPLEX VIRUS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 45. REST OF EUROPE HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  TYPE, 2021-2031 ($MILLION)
  • TABLE 46. REST OF EUROPE HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 47. REST OF EUROPE HERPES SIMPLEX VIRUS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 48. ASIA-PACIFIC HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  TYPE, 2021-2031 ($MILLION)
  • TABLE 49. ASIA-PACIFIC HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 50. ASIA-PACIFIC HERPES SIMPLEX VIRUS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 51. ASIA-PACIFIC HERPES SIMPLEX VIRUS TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 52. JAPAN HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  TYPE, 2021-2031 ($MILLION)
  • TABLE 53. JAPAN HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 54. JAPAN HERPES SIMPLEX VIRUS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 55. CHINA HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  TYPE, 2021-2031 ($MILLION)
  • TABLE 56. CHINA HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 57. CHINA HERPES SIMPLEX VIRUS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 58. INDIA HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  TYPE, 2021-2031 ($MILLION)
  • TABLE 59. INDIA HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 60. INDIA HERPES SIMPLEX VIRUS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 61. AUSTRALIA HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  TYPE, 2021-2031 ($MILLION)
  • TABLE 62. AUSTRALIA HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 63. AUSTRALIA HERPES SIMPLEX VIRUS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 64. SOUTH KOREA HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  TYPE, 2021-2031 ($MILLION)
  • TABLE 65. SOUTH KOREA HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 66. SOUTH KOREA HERPES SIMPLEX VIRUS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 67. REST OF ASIA-PACIFIC HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  TYPE, 2021-2031 ($MILLION)
  • TABLE 68. REST OF ASIA-PACIFIC HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 69. REST OF ASIA-PACIFIC HERPES SIMPLEX VIRUS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 70. LAMEA HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  TYPE, 2021-2031 ($MILLION)
  • TABLE 71. LAMEA HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 72. LAMEA HERPES SIMPLEX VIRUS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 73. LAMEA HERPES SIMPLEX VIRUS TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 74. BRAZIL HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  TYPE, 2021-2031 ($MILLION)
  • TABLE 75. BRAZIL HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 76. BRAZIL HERPES SIMPLEX VIRUS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 77. SAUDI ARABIA HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  TYPE, 2021-2031 ($MILLION)
  • TABLE 78. SAUDI ARABIA HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 79. SAUDI ARABIA HERPES SIMPLEX VIRUS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 80. SOUTH AFRICA HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  TYPE, 2021-2031 ($MILLION)
  • TABLE 81. SOUTH AFRICA HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 82. SOUTH AFRICA HERPES SIMPLEX VIRUS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 83. REST OF LAMEA HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  TYPE, 2021-2031 ($MILLION)
  • TABLE 84. REST OF LAMEA HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 85. REST OF LAMEA HERPES SIMPLEX VIRUS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 86. ABBOTT LABORATORIES: KEY EXECUTIVES
  • TABLE 87. ABBOTT LABORATORIES: COMPANY SNAPSHOT
  • TABLE 88. ABBOTT LABORATORIES: PRODUCT SEGMENTS
  • TABLE 89. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
  • TABLE 90. GLAXOSMITHKLINE PLC: KEY EXECUTIVES
  • TABLE 91. GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
  • TABLE 92. GLAXOSMITHKLINE PLC: PRODUCT SEGMENTS
  • TABLE 93. GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
  • TABLE 94. GLENMARK PHARMACEUTICALS LIMITED: KEY EXECUTIVES
  • TABLE 95. GLENMARK PHARMACEUTICALS LIMITED: COMPANY SNAPSHOT
  • TABLE 96. GLENMARK PHARMACEUTICALS LIMITED: PRODUCT SEGMENTS
  • TABLE 97. GLENMARK PHARMACEUTICALS LIMITED: PRODUCT PORTFOLIO
  • TABLE 98. PFIZER INC.: KEY EXECUTIVES
  • TABLE 99. PFIZER INC.: COMPANY SNAPSHOT
  • TABLE 100. PFIZER INC.: PRODUCT SEGMENTS
  • TABLE 101. PFIZER INC.: PRODUCT PORTFOLIO
  • TABLE 102. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
  • TABLE 103. TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
  • TABLE 104. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT SEGMENTS
  • TABLE 105. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
  • TABLE 106. VIATRIS INC.: KEY EXECUTIVES
  • TABLE 107. VIATRIS INC.: COMPANY SNAPSHOT
  • TABLE 108. VIATRIS INC.: PRODUCT SEGMENTS
  • TABLE 109. VIATRIS INC.: PRODUCT PORTFOLIO
  • TABLE 110. NOVARTIS AG: KEY EXECUTIVES
  • TABLE 111. NOVARTIS AG: COMPANY SNAPSHOT
  • TABLE 112. NOVARTIS AG: PRODUCT SEGMENTS
  • TABLE 113. NOVARTIS AG: PRODUCT PORTFOLIO
  • TABLE 114. FRESENIUS SE AND CO. KGAA: KEY EXECUTIVES
  • TABLE 115. FRESENIUS SE AND CO. KGAA: COMPANY SNAPSHOT
  • TABLE 116. FRESENIUS SE AND CO. KGAA: PRODUCT SEGMENTS
  • TABLE 117. FRESENIUS SE AND CO. KGAA: PRODUCT PORTFOLIO
  • TABLE 118. AMNEAL PHARMACEUTICALS LLC: KEY EXECUTIVES
  • TABLE 119. AMNEAL PHARMACEUTICALS LLC: COMPANY SNAPSHOT
  • TABLE 120. AMNEAL PHARMACEUTICALS LLC: PRODUCT SEGMENTS
  • TABLE 121. AMNEAL PHARMACEUTICALS LLC: PRODUCT PORTFOLIO
  • TABLE 122. AMNEAL PHARMACEUTICALS LLC: KEY STRATERGIES
  • TABLE 123. EMCURE PHARMACEUTICALS LIMITED: KEY EXECUTIVES
  • TABLE 124. EMCURE PHARMACEUTICALS LIMITED: COMPANY SNAPSHOT
  • TABLE 125. EMCURE PHARMACEUTICALS LIMITED: PRODUCT SEGMENTS
  • TABLE 126. EMCURE PHARMACEUTICALS LIMITED: PRODUCT PORTFOLIO

LIST OF FIGURES

  • FIGURE 01. HERPES SIMPLEX VIRUS TREATMENT MARKET, 2021-2031
  • FIGURE 02. SEGMENTATION OF HERPES SIMPLEX VIRUS TREATMENT MARKET, 2021-2031
  • FIGURE 03. TOP INVESTMENT POCKETS IN HERPES SIMPLEX VIRUS TREATMENT MARKET (2022-2031)
  • FIGURE 04. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 05. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 06. MODERATE THREAT OF SUBSTITUTES
  • FIGURE 07. HIGH THREAT OF NEW ENTRANTS
  • FIGURE 08. MODERATE INTENSITY OF RIVALRY
  • FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALHERPES SIMPLEX VIRUS TREATMENT MARKET
  • FIGURE 10. HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  TYPE, 2021(%)
  • FIGURE 11. COMPARATIVE SHARE ANALYSIS OF HERPES SIMPLEX VIRUS TREATMENT MARKET FOR HERPES SIMPLEX VIRUS-1 INFECTION, BY COUNTRY 2021-2031(%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF HERPES SIMPLEX VIRUS TREATMENT MARKET FOR HERPES SIMPLEX VIRUS-2 INFECTION, BY COUNTRY 2021-2031(%)
  • FIGURE 13. HERPES SIMPLEX VIRUS TREATMENT MARKET, BY  DRUG TYPE, 2021(%)
  • FIGURE 14. COMPARATIVE SHARE ANALYSIS OF HERPES SIMPLEX VIRUS TREATMENT MARKET FOR ACYCLOVIR, BY COUNTRY 2021-2031(%)
  • FIGURE 15. COMPARATIVE SHARE ANALYSIS OF HERPES SIMPLEX VIRUS TREATMENT MARKET FOR VALACYCLOVIR, BY COUNTRY 2021-2031(%)
  • FIGURE 16. COMPARATIVE SHARE ANALYSIS OF HERPES SIMPLEX VIRUS TREATMENT MARKET FOR FAMCICLOVIR, BY COUNTRY 2021-2031(%)
  • FIGURE 17. HERPES SIMPLEX VIRUS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021(%)
  • FIGURE 18. COMPARATIVE SHARE ANALYSIS OF HERPES SIMPLEX VIRUS TREATMENT MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY 2021-2031(%)
  • FIGURE 19. COMPARATIVE SHARE ANALYSIS OF HERPES SIMPLEX VIRUS TREATMENT MARKET FOR DRUG STORE AND RETAIL PHARMACIES, BY COUNTRY 2021-2031(%)
  • FIGURE 20. COMPARATIVE SHARE ANALYSIS OF HERPES SIMPLEX VIRUS TREATMENT MARKET FOR ONLINE PROVIDERS, BY COUNTRY 2021-2031(%)
  • FIGURE 21. HERPES SIMPLEX VIRUS TREATMENT MARKET BY REGION, 2021
  • FIGURE 22. U.S. HERPES SIMPLEX VIRUS TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 23. CANADA HERPES SIMPLEX VIRUS TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 24. MEXICO HERPES SIMPLEX VIRUS TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 25. GERMANY HERPES SIMPLEX VIRUS TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 26. FRANCE HERPES SIMPLEX VIRUS TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 27. UK HERPES SIMPLEX VIRUS TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 28. ITALY HERPES SIMPLEX VIRUS TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 29. SPAIN HERPES SIMPLEX VIRUS TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 30. REST OF EUROPE HERPES SIMPLEX VIRUS TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 31. JAPAN HERPES SIMPLEX VIRUS TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 32. CHINA HERPES SIMPLEX VIRUS TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 33. INDIA HERPES SIMPLEX VIRUS TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 34. AUSTRALIA HERPES SIMPLEX VIRUS TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 35. SOUTH KOREA HERPES SIMPLEX VIRUS TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 36. REST OF ASIA-PACIFIC HERPES SIMPLEX VIRUS TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 37. BRAZIL HERPES SIMPLEX VIRUS TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 38. SAUDI ARABIA HERPES SIMPLEX VIRUS TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 39. SOUTH AFRICA HERPES SIMPLEX VIRUS TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 40. REST OF LAMEA HERPES SIMPLEX VIRUS TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 41. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 42. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 43. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 44. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 45. COMPETITIVE DASHBOARD
  • FIGURE 46. COMPETITIVE HEATMAP: HERPES SIMPLEX VIRUS TREATMENT MARKET
  • FIGURE 47. TOP PLAYER POSITIONING, 2021
  • FIGURE 48. ABBOTT LABORATORIES: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 49. ABBOTT LABORATORIES: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 50. ABBOTT LABORATORIES: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 51. GLAXOSMITHKLINE PLC: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 52. GLENMARK PHARMACEUTICALS LIMITED: NET SALES, 2019-2021 ($MILLION)
  • FIGURE 53. GLENMARK PHARMACEUTICALS LIMITED: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 54. PFIZER INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 55. PFIZER INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 56. PFIZER INC.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 57. TEVA PHARMACEUTICAL INDUSTRIES LTD.: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 58. TEVA PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 59. VIATRIS INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 60. VIATRIS INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 61. NOVARTIS AG: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 62. NOVARTIS AG: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 63. NOVARTIS AG: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 64. FRESENIUS SE AND CO. KGAA: NET SALES, 2019-2021 ($MILLION)
  • FIGURE 65. FRESENIUS SE AND CO. KGAA: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 66. FRESENIUS SE AND CO. KGAA: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 67. AMNEAL PHARMACEUTICALS LLC: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 68. AMNEAL PHARMACEUTICALS LLC: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 69. EMCURE PHARMACEUTICALS LIMITED: NET REVENUE, 2018-2020 ($MILLION)
  • FIGURE 70. EMCURE PHARMACEUTICALS LIMITED: REVENUE SHARE BY REGION, 2020 (%)